Scrip
FDA continues "safety review" of potential link between bisphosphonates and fractures
11 March 2010
Nancy Faigen
Please Login to read the full article.
11 March 2010
Nancy Faigen
The
US FDA has announced an "ongoing safety review" of oral bisphosphosphonates to see if they are potentially linked to atypical subtrochanteric femur fractures, or fractures in the bone just below the hip joint. For the data reviewed to date, there is no clear connection, the regulator...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE osteoporotic fracture guidance unchanged despite legal challenge
- Amgen's bone drug as good as Zometa in patients with solid tumours
- NICE to review guidance on Servier's Protelos after legal challenge
- US doctors likely to keep denosumab as second- or third-line therapy for PMO
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
